The Centers for Medicare and Medicaid Services earlier this year reportedly quashed a plan pay for Novartis’ roughly $500,000 cancer treatment, throwing a kink in President Donald Trump’s mission to slash drug prices.
According to a POLITICO report, the arranged payment was suspended after officials questioned whether the drugmaker may have received special treatment from President Donald Trump’s administration after having paid Trump’s lawyer, Michael Cohen, about $1.2 million in 2017 for some consulting work.
POLITICO reports there is “no indication” the lawyer had any involvement in the Kymriah arrangement.
CMS had said the performance-based payment deal would save lives and trim back Medicare and Medicaid’s spending. Seven months after touting the deal, according to the POLITICO report, CMS backed out of the deal, providing little explanation.
“Though the agency won’t say why, emails obtained by POLITICO show that administration lawyers expressed discomfort over how much Novartis itself was influencing the arrangement, including giving advice on the payment criteria for Kymriah,” the POLITICO report states.
To read the full report on POLITICO, click here.